Dynavax Technologies Corporation (DVAX)
| Market Cap | 1.19B |
| Revenue (ttm) | 294.62M |
| Net Income (ttm) | -60.07M |
| Shares Out | 122.41M |
| EPS (ttm) | -0.47 |
| PE Ratio | n/a |
| Forward PE | 19.98 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,195,280 |
| Open | 9.60 |
| Previous Close | 9.72 |
| Day's Range | 9.30 - 9.89 |
| 52-Week Range | 9.74 - 14.63 |
| Beta | 1.26 |
| Analysts | Buy |
| Price Target | 26.25 (+170.9%) |
| Earnings Date | May 6, 2025 |
About DVAX
Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States and internationally. The company offers HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in adults aged 18 years and older; and CpG 1018, the adjuvant used in HEPLISAV-B. It also develops rF1V, a plague vaccine candidate in Phase 2 clinical trial; and Z-1018, an investigational vaccine candidate in Phase 1/2 clinical trial for the pr... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for DVAX stock is "Buy." The 12-month stock price forecast is $26.25, which is an increase of 170.90% from the latest price.
News
Dynavax Issues Statement and Mails Letter to Stockholders Emphasizing Record Financial Results and Continued Momentum
Deep Track's Misleading Investor Presentation Demonstrates its Single-Minded Approach to Abandon Long-Term Value Opportunities in Exchange for Short-Term Return Urges Stockholders to Vote "FOR" All Fo...
Dynavax Technologies Corporation (DVAX) Q1 2025 Earnings Call Transcript
Dynavax Technologies Corporation (NASDAQ:DVAX) Q1 2025 Earnings Conference Call May 6, 2025 4:30 PM ET Company Participants Paul Cox - Vice President, Investor Relations & Corporate Communications Ry...
Dynavax Reports First Quarter 2025 Financial Results and Announces New Pipeline Programs
Record HEPLISAV-B® first quarter net product revenue of $65 million, representing 36% year-over-year growth Top-line results in Part 1 of Phase 1/2 shingles vaccine trial expected in Q3 2025 New pande...
Deep Track Capital Releases Investor Presentation on Dynavax Technologies
GREENWICH, Conn.--(BUSINESS WIRE)--Deep Track Capital, LP, (together with its affiliates, “Deep Track” or “we”) one of the largest shareholders of Dynavax Technologies Corporation (NASDAQ: DVAX) (“Dyn...
Dynavax Announces Nationwide Harris Poll Survey Results Finding Americans Underestimate the Serious Consequences of Hepatitis B and Vaccine Protection Benefits
Over half of American adults do not know chronic hepatitis B can cause liver disease such as cirrhosis and liver cancer Half of American adults were unaware that anyone can be at risk for the hepatiti...
Dynavax Highlights Superior Board Leadership Overseeing Long-Term Value Creation Strategy
Mails Letter to Stockholders Urging Stockholders to Vote "FOR" All Four Dynavax Director Nominees on the GOLD Proxy Card EMERYVILLE, Calif. , April 29, 2025 /PRNewswire/ -- Dynavax Technologies Corpor...
Dynavax to Report First Quarter 2025 Financial Results and Host Conference Call on May 6, 2025
EMERYVILLE, Calif. , April 22, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, wi...
Deep Track Capital Files Definitive Proxy Statement and Sends Letter to Fellow Shareholders
GREENWICH, Conn.--(BUSINESS WIRE)--Deep Track Capital, LP, (together with its affiliates, “Deep Track” or “we”), one of the largest shareholders of Dynavax Technologies Corporation (NASDAQ: DVAX) (“Dy...
Dynavax Files Definitive Proxy Statement and Sends Letter to Stockholders
Urges Stockholders to Vote "FOR" All Four Dynavax Director Nominees on the GOLD Proxy Card Highlights Record Financial and Operational Results, Balanced Capital Allocation Strategy andMeaningful Board...
Deep Track Capital Comments on Dynavax Technologies' Rejection of Most Recent Settlement Offer
GREENWICH, Conn.--(BUSINESS WIRE)--Deep Track Capital, LP, (together with its affiliates, “Deep Track” or “we”) is one of the largest shareholders of Dynavax Technologies Corporation (NASDAQ: DVAX) (“...
Dynavax Files Preliminary Proxy Statement
Dynavax's Board is Overseeing Record Operational and Financial Performance Outlines Extensive Engagement with Deep Track and Multiple Attempts to Reach a Resolution EMERYVILLE, Calif. , April 3, 2025 ...
Deep Track Capital Sends Letter to Dynavax Technologies' Board of Directors
GREENWICH, Conn.--(BUSINESS WIRE)--Deep Track Capital, LP, (together with its affiliates, “Deep Track” or “we”), one of the largest shareholders of Dynavax Technologies Corporation (NASDAQ: DVAX) (“Dy...
Dynavax Announces Convertible Debt Refinancing and Common Stock Share Repurchase
Opportunistic refinancing extends the maturity of most of existing debt with improved terms and reduces dilution to existing capital structure $225 million of convertible notes due in 2030 issued, inc...
Dynavax Technologies: A Post-Earnings Assessment With Growing Market Share
Dynavax Technologies posted solid Q4 results and FY 2025 guidance late in February, with Heplisav-B driving revenue growth and profitability. Heplisav-B's market share continues to grow due to its sup...
Dynavax to Participate in Upcoming Investor Conferences
EMERYVILLE, Calif. , Feb. 25, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, tod...
Dynavax Technologies Corporation (DVAX) Q4 2024 Earnings Call Transcript
Dynavax Technologies Corporation (NASDAQ:DVAX) Q4 2024 Earnings Conference Call February 20, 2025 4:30 PM ET Company Participants Paul Cox - Vice President, Investor Relations & Corporate Communicati...
Dynavax Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 Financial Guidance
HEPLISAV-B® 2024 net product revenue grew 26% year-over-year to $268 million; net product revenue expected to be $305 to $325 million in 2025 Top-line results in Phase 1/2 shingles trial expected in Q...
Dynavax Responds to Deep Track and Highlights Long-Term Value Creation Strategy
Reiterates Meaningful Board Change Already Underway EMERYVILLE, Calif. , Feb. 19, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) ("Dynavax" or the "Company"), a commercial-stage ...
Deep Track Capital Nominates Four Highly Qualified Candidates for Election to Dynavax Technologies' Board of Directors at 2025 Annual Meeting
GREENWICH, Conn.--(BUSINESS WIRE)--Deep Track Capital, LP, (together with its affiliates, “Deep Track” or “we”), one of the largest shareholders of Dynavax Technologies Corporation (NASDAQ: DVAX) (“Dy...
Exclusive: Investor Deep Track launches proxy fight at Dynavax, nominates 4 directors
Life sciences investment firm Deep Track Capital is launching a board fight at Dynavax Technologies , pressing for new directors to prioritize the development of the company's hepatitis B vaccine inst...
Goldman Sachs Turns Bearish On Vaccine Maker Dynavax Amid Shingles And Hepatitis B Uncertainty
Goldman Sachs downgraded Dynavax Technologies Corporation DVAX reflecting updated views and recent competitive dynamics for vaccines.
Dynavax to Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on February 20, 2025
EMERYVILLE, Calif. , Feb. 6, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will...
Dynavax Advances Board Refreshment Program
Appoints Emilio Emini and Lauren Silvernail to Board of Directors; Two Directors to Step Down at 2025 Annual Meeting Intends to Seek Stockholder Approval for Declassification of Board at 2025 Annual M...
Dynavax Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Highlights
Preliminary 2024 HEPLISAV-B® net product revenue grew 26% year-over-year to approximately $268 million Enrollment completed in Phase 1/2 shingles trial; top line results expected in Q3 2025 New $30 mi...
Dynavax to Present at the 7th Annual Evercore HealthCONx Conference
EMERYVILLE, Calif. , Nov. 26, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, tod...